公开(公告)号：US10167339B2

公开(公告)日：2019-01-01

申请号：US15501526

申请日：2015-08-03

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Yong-Jun Liu ,  Sandra Zurawski ,  SangKon Oh ,  Shino Hanabuchi ,  Haruyuki Fujita ,  Hideki Ueno ,  Patrick Blanco ,  Hyemee Joo

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/28

Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-α and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.

公开(公告)号：US20150064205A1

公开(公告)日：2015-03-05

申请号：US14484599

申请日：2014-09-12

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon Oh ,  Jacques F. Banchereau ,  Gerard Zurawski ,  Hideki Ueno ,  Ling Ni

IPC: C07K16/28 ,  A61K47/42 ,  A61K47/36

CPC classification number: C07K16/2851 ,  A61K39/12 ,  A61K39/145 ,  A61K39/385 ,  A61K39/39 ,  A61K47/36 ,  A61K47/42 ,  A61K2039/55572 ,  A61K2039/6056 ,  C07K2317/76 ,  C07K2319/035 ,  C12N2760/16134

Abstract: Compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses are disclosed herein. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of pathogenic infections.

Abstract translation: 本文公开了用于增强Th1 / Th17细胞应答和降低Th2细胞应答的组合物和方法。 在各种实施方案中，本发明描述了在含有Dectin-1的人树状细胞中激活人树突状细胞的活化和增强抗原特异性T细胞应答，所述树突细胞包含与一种或多种抗原融合的抗Dectin-1特异性抗体或其片段 。 还可以包括TLR2配体以增强T细胞反应的活化和增强。 此外，本发明还包括基于本文所述的用于治疗病原体感染的组合物的方法。

公开(公告)号：US10570208B2

公开(公告)日：2020-02-25

申请号：US16210188

申请日：2018-12-05

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Yong-Jun Liu ,  Sandra Zurawski ,  SangKon Oh ,  Shino Hanabuchi ,  Haruyuki Fujita ,  Hideki Ueno ,  Patrick Blanco ,  Hyemee Joo

IPC: C07H21/04 ,  C12P21/06 ,  C12N5/00 ,  C07K16/00 ,  C12P21/08 ,  C07K16/28 ,  A61K39/00

Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-α and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.

公开(公告)号：US20190092869A1

公开(公告)日：2019-03-28

申请号：US16210188

申请日：2018-12-05

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Yong-Jun Liu ,  Sandra Zurawski ,  SangKon Oh ,  Shino Hanabuchi ,  Haruyuki Fujita ,  Hideki Ueno ,  Patrick Blanco ,  Hyemee Joo

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2875 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76

Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-α and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.